149 related articles for article (PubMed ID: 12604270)
1. Low-dose tacrolimus for intractable myasthenia gravis.
Yoshikawa H; Mabuchi K; Yasukawa Y; Takamori M; Yamada M
J Clin Neurosci; 2002 Nov; 9(6):627-8. PubMed ID: 12604270
[TBL] [Abstract][Full Text] [Related]
2. Adequate tacrolimus concentration for myasthenia gravis treatment.
Kanai T; Uzawa A; Kawaguchi N; Himuro K; Oda F; Ozawa Y; Kuwabara S
Eur J Neurol; 2017 Feb; 24(2):270-275. PubMed ID: 28102047
[TBL] [Abstract][Full Text] [Related]
3. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis.
Tada M; Shimohata T; Tada M; Oyake M; Igarashi S; Onodera O; Naruse S; Tanaka K; Tsuji S; Nishizawa M
J Neurol Sci; 2006 Aug; 247(1):17-20. PubMed ID: 16631797
[TBL] [Abstract][Full Text] [Related]
4. Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells.
Utsugisawa K; Nagane Y; Yonezawa H; Obara D; Kondoh R; Tohgi H
Muscle Nerve; 2003 Feb; 27(2):245-8. PubMed ID: 12548534
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone.
Shimojima Y; Matsuda M; Gono T; Ishii W; Tokuda T; Ikeda S
J Clin Neurosci; 2006 Jan; 13(1):39-44. PubMed ID: 16307880
[TBL] [Abstract][Full Text] [Related]
6. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study.
Ponseti JM; Azem J; Fort JM; Codina A; Montoro JB; Armengol M
Clin Neurol Neurosurg; 2005 Apr; 107(3):187-90. PubMed ID: 15823673
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous and sustained remission of intractable myasthenia gravis and focal segmental glomerulosclerosis with tacrolimus treatment.
Chung S; Park CW; Song J; Kim JA; Shin SJ; Chang YS
Clin Nephrol; 2008 Jul; 70(1):59-61. PubMed ID: 18793550
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus.
Nagaishi A; Yukitake M; Kuroda Y
Intern Med; 2008; 47(8):731-6. PubMed ID: 18421189
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Cervera C; Armengol M
Neurology; 2005 May; 64(9):1641-3. PubMed ID: 15883336
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of tacrolimus on myasthenia gravis with thymoma.
Mitsui T; Kunishige M; Ichimiya M; Shichijo K; Endo I; Matsumoto T
Neurologist; 2007 Mar; 13(2):83-6. PubMed ID: 17351528
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with prednisolone and tacrolimus for myasthenia gravis with invasive thymoma.
Miura S; Azuma K; Yamada K; Takamori S; Kawahara A; Noda K; Ayabe M; Kage M; Aizawa H; Taniwaki T
Acta Neurol Belg; 2010 Mar; 110(1):107-9. PubMed ID: 20514937
[TBL] [Abstract][Full Text] [Related]
12. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.
Minami N; Fujiki N; Doi S; Shima K; Niino M; Kikuchi S; Sasaki H
J Neurol Sci; 2011 Jan; 300(1-2):59-62. PubMed ID: 21035148
[TBL] [Abstract][Full Text] [Related]
13. Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis.
Nishida Y; Takahashi YK; Kanai T; Nose Y; Ishibashi S; Sanjo N; Uzawa A; Oda F; Ozawa Y; Kuwabara S; Noguchi E; Suzuki S; Nakahara J; Suzuki N; Ogawa T; Yokoyama K; Hattori N; Konno S; Fujioka T; Kawaguchi N; Hatanaka Y; Sonoo M; Kaneko J; Ogino M; Nishiyama K; Nomura K; Yokota T
Eur J Neurol; 2020 Jan; 27(1):100-104. PubMed ID: 31309642
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis.
Wakata N; Saito T; Tanaka S; Hirano T; Oka K
Clin Neurol Neurosurg; 2003 Dec; 106(1):5-8. PubMed ID: 14643908
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis.
Zhao CB; Zhang X; Zhang H; Hu XQ; Lu JH; Lu CZ; Xiao BG
Int Immunopharmacol; 2011 Apr; 11(4):519-24. PubMed ID: 21195813
[TBL] [Abstract][Full Text] [Related]
16. [A child with generalized myasthenia gravis successfully treated with tacrolimus].
Goto T; Mori M; Yamagata T; Mizuguchi M; Momoi MY
No To Hattatsu; 2007 Jul; 39(4):300-3. PubMed ID: 17633089
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis.
Wang L; Xi J; Zhang S; Wu H; Zhou L; Lu J; Zhang T; Zhao C
J Clin Neurosci; 2019 May; 63():160-167. PubMed ID: 30827886
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus).
Konishi T; Yoshiyama Y; Takamori M; Saida T
J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):448-50. PubMed ID: 15716549
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic efficacy and safety of tacrolimus for intractable myasthenia gravis: a report of 36 patients].
Feng HY; Liu WB; Qiu L; Huang X; Huang RX
Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(45):3190-2. PubMed ID: 22333101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
